ArticleResearch square2026
A lipidomic based metabolic age score for monitoring the effects of lifestyle and diet on metabolic disease risk.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
Biological age scores capture ageing heterogeneity beyond chronological age but are often dominated by lifestyle and environmental exposures, limiting clinical interpretability. We developed an environmentally adjusted metabolic age score (EAmAge) to isolate intrinsic ageing biology relevant to neurodegeneration and chronic disease. Major environmental influences were statistically removed from plasma lipidomic profiles before constructing an age-prediction model using ridge regression. EAmAge was derived in the AusDiab cohort (n = 10,339) and validated across three independent cohorts (BHS, ADNI and ASPREE; total n = 9,835). Compared with an unadjusted lipidomic age model (mAge_orig), EAmAge showed stronger and more consistent associations with incident Alzheimer s disease-related dementia, cardiovascular events and all-cause mortality. EAmAge was also associated with Alzheimer s disease-related biomarkers, including amyloid burden, reduced glucose metabolism and hippocampal atrophy. These findings establish EAmAge as a robust and partially modifiable biomarker that improves risk stratification by disentangling intrinsic metabolic ageing from environmental confounding.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.